Vivos Therapeutics announces the formation of a new


HIGHLANDS RANCH, Colorado, September 23, 2021 (GLOBE NEWSWIRE) – Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on the development and commercialization of innovative treatments for patients with mild to moderate obstructive sleep apnea (OSA) and snoring , today announced the official formation of the Vivos Medical Consortium. This working group of physicians will collaborate to advance the technological capabilities of Vivos OSA and include renowned physicians specializing in sleep medicine, neurology, pediatrics, pulmonology, anesthesiology, pain medicine, otolaryngology, obstetrics. and gynecology, cardiology, and forensics from leading academic institutions in the United States and Canada.

Led by Drs. Clete Kushida of Stanford University and Cecilia Wu of the University of Alberta, the Vivos Medical Consortium will assist the Company in the planning, dissemination and conduct of key research initiatives, enhancing physician-dentist collaborations and expanding new applications of Vivos technology to other medical conditions.

Members of the Vivos Medical Consortium include:

  • Clete Kushida MD PhD (co-chair), division chief and medical director of sleep medicine; Neurologist, Professor and Associate Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University
  • Cecilia Wu MD (co-chair), Anatomy, Cardiovascular and Forensic Pathology; Assistant Clinical Professor, University of Alberta
  • Fred Lin MD, head of the sleep surgery division; Assistant professor; Department of Otolaryngology – Head and Neck Surgery, Icahn School of Medicine at Mount Sinai
  • Manisha Witmans MD, specialist in sleep medicine and pediatric pulmonology; Associate Clinical Professor, University of Alberta
  • Samuel DeMaria MD, professor of anesthesiology, perioperative and pain medicine and otolaryngology; Vice President for Research, Icahn School of Medicine at Mount Sinai
  • Seth Heckman MD, Obstetrics and Gynecology; Assistant Clinical Professor of Family Medicine, University of Alberta
  • Yury Khelemsky MD, program director, pain medicine fellowship; associate professor, Department of Anesthesiology, Perioperative and Pain Medicine; Department of Neurology, Icahn School of Medicine at Mount Sinai

“Every specialty in medicine deals in one way or another with the negative impact of obstructive sleep apnea, with the end stage of untreated sleep apnea comprising a decrease in quality of life, heart and metabolic disease and the potential for premature death, “said Dr. Wu.” Today more than ever, we see the critical importance of optimizing personal health. For decades, the only treatment options for sleep apnea were limited and often invasive, but with Vivos technology that has changed dramatically. Our physician working group has been impressed with the potential impact of Vivos technology and its applications, and I am delighted to co-lead the Vivos Medical Consortium with Dr. Kushida as we help guide scientific advancements and the company’s research efforts, as well as increasing awareness of Vivos technology in the medical field.

Commenting on the expected impact of the Vivos Medical Consortium, Vivos Chairman and CEO Kirk Huntsman said, “Obstructive sleep apnea is a serious medical problem, but it is a problem that, through use of Vivos technology, now has a very effective medical solution. which can be issued by a dentist. Under the leadership of the Vivos Medical Consortium, we look forward to continuing to advance our technology and presence in the medical and dental communities and to fulfill our mission statement to combat this devastating disease by addressing the underlying cause of the disease. OSA with minimal impact on quality of life. We hope that our medical consortium will facilitate wider adoption of our technology for patients who would benefit from our non-surgical and non-invasive solution. “

Members of the Medical Consortium will serve as consultants for Vivos and will receive usual compensation in cash and shares.

About Vivos Therapeutics, Inc.
Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on the development and commercialization of innovative diagnostic and treatment modalities for adult patients with respiratory sleep disorders, including obstructive sleep apnea ( AOS). Vivos treatment for mild to moderate OSA involves a personalized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first non-surgical, non-invasive, non-pharmaceutical and cost-effective clinically effective solution for people with mild to moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos oral appliances have been shown to be effective in more than 19,000 patients worldwide by more than 1,250 dentists. Combining technologies and protocols that alter the size, shape, and position of a patient’s upper airway tissue, the Vivos system opens up airway space and can dramatically reduce symptoms and conditions associated with Mild to moderate OSA, such as lowering the apnea-hypopnea index scores. Vivos also markets and distributes VivosScore, powered by SleepImage diagnostic technology for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program provides dentists with training and other value-added services related to the use of the Vivos system.

For more information visit

Caution Regarding Forward-Looking Statements
This press release and the statements of the management of the Company in this regard contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended) relating to future events, in particular in relation to the public offering described herein. Words such as “may”, “should”, “expects”, “plans”, “intends”, “plans”, “believes”, “plans”, “hopes”, “believes” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based on several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the anticipated benefits of Vivos Medical Consortium as described in this document) may differ materially from those expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include, without limitation, the risk factors described in documents filed by Vivos with the Securities and Exchange Commission (“SEC”). The documents filed by Vivos can be obtained free of charge from the SEC’s website at Except to the extent required by law, Vivos expressly disclaims any obligation or commitment to publicly release any update or revision to any forward-looking statement contained herein to reflect any change in Vivos’ expectations in this regard or any change in the events, conditions or circumstances upon which any statement is based.

Investor Relations Contact:
Edouard Loew
Investor Relations Officer
(602) 903-0095
[email protected]

Contact person for media relations:
Caitlin Kasunich / Jenny Robles
KCSA strategic communication
(212) 896-1241 / (212) 896-1231
[email protected] / [email protected]


About Hector Hedgepeth

Check Also

Folbigg’s life and advances in genetic research

New South Wales will conduct a second inquiry into Kathleen Folbigg’s convictions. At the center …

Leave a Reply

Your email address will not be published.